Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Clinical Cancer Research
Clinical Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Imaging, Diagnosis, Prognosis

In Situ Tumor PD-L1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast Carcinomas

Kurt A. Schalper, Vamsidhar Velcheti, Daniel Carvajal, Hallie Wimberly, Jason Brown, Lajos Pusztai and David L. Rimm
Kurt A. Schalper
Departments of 1Pathology and 2Medical Oncology, Yale School of Medicine, New Haven, Connecticut; and 3Department of Solid Tumor Oncology, Cleveland Clinic, Cleveland, Ohio
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vamsidhar Velcheti
Departments of 1Pathology and 2Medical Oncology, Yale School of Medicine, New Haven, Connecticut; and 3Department of Solid Tumor Oncology, Cleveland Clinic, Cleveland, Ohio
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel Carvajal
Departments of 1Pathology and 2Medical Oncology, Yale School of Medicine, New Haven, Connecticut; and 3Department of Solid Tumor Oncology, Cleveland Clinic, Cleveland, Ohio
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hallie Wimberly
Departments of 1Pathology and 2Medical Oncology, Yale School of Medicine, New Haven, Connecticut; and 3Department of Solid Tumor Oncology, Cleveland Clinic, Cleveland, Ohio
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jason Brown
Departments of 1Pathology and 2Medical Oncology, Yale School of Medicine, New Haven, Connecticut; and 3Department of Solid Tumor Oncology, Cleveland Clinic, Cleveland, Ohio
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lajos Pusztai
Departments of 1Pathology and 2Medical Oncology, Yale School of Medicine, New Haven, Connecticut; and 3Department of Solid Tumor Oncology, Cleveland Clinic, Cleveland, Ohio
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David L. Rimm
Departments of 1Pathology and 2Medical Oncology, Yale School of Medicine, New Haven, Connecticut; and 3Department of Solid Tumor Oncology, Cleveland Clinic, Cleveland, Ohio
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1078-0432.CCR-13-2702 Published May 2014
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Purpose: Blockade of the PD-1/PD-L1 axis emerged as a promising new therapeutic option for cancer that has resulted in lasting responses in metastatic renal, lung carcinomas, and melanomas. Tumor PD-L1 protein expression may predict response to drugs targeting this pathway. Measurement of PD-L1 protein is limited by the lack of standardized immunohistochemical methods and variable performance of antibodies. Our goal was to correlate PD-L1 mRNA expression with clinical variables in primary breast carcinomas.

Experimental Design: The fluorescent RNAscope paired-primer assay was used to quantify in situ PD-L1 mRNA levels in 636 stage I–III breast carcinomas on two sets of tissue microarrays [YTMA128 (n = 238) and YTMA201 (n = 398)]. Tumor-infiltrating lymphocytes (TIL) were assessed by hematoxylin/eosin stain and quantitative fluorescence.

Results: On YTMA128 and YTMA201, 55.7% and 59.5% of cases showed PD-L1 mRNA expression, respectively. Higher PD-L1 mRNA expression was significantly associated with increased TILs (P = 0.04) but not with other clinical variables. Elevated TILs (scores 2 and 3+) occurred in 16.5% on YTMA128 and 14.8% on YTMA201 and was associated with estrogen receptor–negative status (P = 0.01 on YTMA128 and 0.0001 on YTMA201). PD-L1 mRNA expression was associated with longer recurrence-free survival (log-rank P = 0.01), which remained significant in multivariate analysis including age, tumor size, histologic grade, nodal metastasis, hormone receptor, HER2 status, and the extent of TILs (HR, 0.268; CI, 0.099–0.721; P = 0.009).

Conclusions: PD-L1 mRNA expression is identified in nearly 60% of breast tumors and it is associated with increased TILs and improved recurrence-free survival. These observations support the evaluation of PD-1/PD-L1–targeted therapies in breast cancer. Clin Cancer Res; 20(10); 2773–82. ©2014 AACR.

Translational Relevance

The presence of tumor-infiltrating lymphocytes in breast cancer is associated with better prognosis and higher response to preoperative chemotherapy. Unfortunately, the prognostic and predictive value of tumor immune infiltrates is significant but modest. In most instances, the immune system mounts only a partially effective antitumor response. Expression of Programmed death ligand-1 (PD-L1) is a key mechanism of tumor immune evasion. PD-L1 is expressed in various human cancers and tumor PD-L1 protein positivity using immunohistochemistry predicted response to anti-PD1 monoclonal antibody therapy. The literature suggests the different immunohistochemical methods yield discordant results that hinder progress in this field. Herein, we describe a reproducible, antibody-independent, and compartment-specific method of measuring PD-L1 mRNA in formalin-fixed, paraffin-embedded tissue samples and demonstrate the prognostic value of this marker in breast cancer. Further evaluation of PD-L1 mRNA in a prospective clinical trial may help select patients for immunostimulatory drugs targeting the PD-1/PD-L1 pathway.

Introduction

Breast cancers harbor a large number of genomic alterations that can result in mutated proteins. These mutations not only contribute to the malignant transformation but also lead to neoantigens that may serve as targets for a local immune response, which could exert some control on tumor growth (1). Indeed, the presence of lymphocytes in the tumor microenvironment (TILs) and gene expression signatures representative of these cells have long been associated with (slightly but significantly) better prognosis, particularly among high-grade and estrogen receptor (ER)-negative tumors (2–5). Numerous attempts have been made in the past to exploit adoptive immunotherapy in breast cancer (e.g., vaccines, cytokines) that have met with limited success (6). It is increasingly recognized that inhibition of TIL activity in the tumor microenvironment limits the extent of antitumor immune response (7).

Recent evidence highlights the pivotal role of the PD-1 (programmed cell death-1) receptor pathway in maintaining an immunosuppressive tumor microenvironment. PD-1 is a member of the B7-CD28 family of T-cell coregulatory receptors and contributes inhibitory signals that mediate the physiologic immune tolerance and limit the inflammatory response to infections (8, 9). PD-1 is expressed in various immune cell types and its activation attenuates T-cell function, survival, and expansion (10, 11). The PD-1 ligand, PD-L1 is expressed on activated T cells, B cells, dendritic cells, and macrophages, in addition to some immune-privileged non-hematopoietic tissues (e.g., retina and placenta; refs. 12, 13). Tumors from diverse locations can express PD-L1, including breast, ovarian, gastric, pancreatic, lung, and renal cell carcinomas (14–18). PD-L1 expression by tumor cells is believed to mediate the inhibition of local immune responses, thus shielding the tumor from T-cell–mediated killing. In support of this notion, early-phase trials using monoclonal antibodies targeting PD-1 or PD-L1 have shown substantive and durable clinical responses in patients with refractory solid tumors, including melanoma, renal, and non–small cell lung carcinomas (19, 20).

PD-L1 protein has been reported not to be expressed in normal breast but to be increased in nearly half of breast cancers, particularly in hormone receptor–negative and high-grade, proliferative tumors (14, 21). In addition, high PD-L1 protein expression in TILs from breast cancer specimens was observed in large, high-grade HER2-positive tumors. The presence of regulatory T cells (Tregs), tumor PD-L1 expression, and PD-1–positive TILs was associated with high histologic grade, ER negativity, and prominent lymphocytic infiltrates (22). Preliminary data show that tumor PD-L1 protein expression using immunohistochemistry (IHC) in formalin-fixed, paraffin-embedded (FFPE) tissue may predict response to drugs targeting the PD-1/PD-L1 pathway (19). However, the PD-L1 threshold for expression is not well defined and is subject to assay and interpretative subjectivity. In addition, the specificity and reproducibility of most commercially available anti-PD-L1 antibodies has not been thoroughly assessed and limitations of some widely used antibodies have been communicated (23). Therefore, it is not surprising that some authors have found association of tumor PD-L1 protein expression with adverse outcome (24–28), while others found no association with outcome or association with longer survival using comparable methods (24, 29–32). The use of alternative methods to accurately assess PD-L1 status in biologic and clinical samples could help overcome such limitations.

We report herein a novel antibody-independent and tissue compartment–specific assay for in situ PD-L1 mRNA measurement in tumor FFPE tissues using the RNAscope assay coupled to quantitative fluorescence (AQUA). We show that PD-L1 mRNA positivity is associated with increased TILs and longer event-free survival in breast cancer.

Materials and Methods

Patient cohorts, tissue microarrays, and control preparations

Two previously reported (33, 34) retrospective stage I–III breast cancer collections from Yale University (New Haven, CT) represented in tissue microarray (TMA) format were used in this study, termed YTMA128 (N = 238) and YTMA201 (N = 398). Clinicopathologic information from patients in both cohorts was collected from clinical records and pathology reports. The major clinicopathologic characteristics and available treatment information of the cohorts are presented in Supplementary Table S1. Because of the lack of extensive follow-up and limited events on the newer cohort, YTMA128, survival analysis was performed only on YTMA201. Tissue specimens were included in a TMA format as described (35, 36). Briefly, representative tumor areas were selected in hematoxylin/eosin–stained preparations by a pathologist and 0.6 mm cores were obtained using a needle and arrayed in a recipient block. A control TMA termed YTMA245 was constructed for reagents titration, PD-L1 mRNA assay validation, and reproducibility assessment. This index TMA contained FFPE samples from carcinomas, human placenta, and parental/PD-L1–transfected Mel624 cells. Culture conditions and cell line TMA construction have been reported elsewhere (35, 36).

In situ mRNA hybridization

In situ detection of PD-L1 transcripts in FFPE TMA samples was performed using the RNAscope assay with custom-designed in situ hybridization probes (Advanced Cell Diagnostics) coupled to automated quantitative fluorescence (QIF) detection as described (33–35). Briefly, 5 μm sections were deparaffinized, boiled with preamplification reagent for 15 minutes, and submitted to protease digestion followed by hybridization for 2 hours with target probes to human PD-L1 mRNA, Ubiquitin C (UbC) as a positive control, or the bacterial gene DapB mRNA as a negative control. Hybridization signals were detected with Cy5-tyramide. Preparations were then incubated with a wide-spectrum rabbit anti-cow cytokeratin antibody (clone Z0622 1:100, DAKO Corp) in bovine serum albumin/Tris-buffered saline for 1 hour followed by detection with a secondary Alexa-546 conjugated goat-anti-rabbit antibody (1:100, Molecular Probes). Slides were mounted using ProlongGold plus 4′,6-diamidino-2-phenylindole (DAPI) to highlight nuclei. Assay specificity was assessed measuring the signal in positive and negative control samples. Reproducibility was assessed by staining control preparations on different days using the same protocol and determining the linear regression coefficients (R2) between such runs.

Automated quantitative fluorescence

QIF using the AQUA method enables objective and sensitive measurement of targets within user-defined tissue compartments (33–35, 37, 38). Briefly, the QIF score of mRNA signal in the tumor was calculated by dividing the target mRNA pixel intensities with the area of the tumor compartment defined by the cytokeratin positivity. Scores were normalized to the exposure time and bit depth at which the images were captured, allowing scores collected at different exposure times to be comparable. The experimenters visually evaluated all acquired histospots and cases with staining artifacts and/or presence of less than 2% tumor were excluded. As shown in Supplementary Fig. S3, PD-L1 protein was measured using QIF with the validated mouse monoclonal antibody clone 5h1 as recently reported (35). Detailed description of PD-L1 protein staining is provided in the Supplementary Methods.

Evaluation of tumor-infiltrating lymphocytes

The scoring of TILs was performed in hematoxylin/eosin–stained TMA preparations independently by two pathologists (K.A. Schalper and D. Carvajal) using a four-tiered scale based on the visual estimation of the amount of lymphocytes in each histospot, as described (39). A score of 0 indicated virtual absence of TILs; 1+, low TILs (<30%); 2+, moderate (30%–60%); and 3+, marked increase in the lymphocytic infiltrate (>60%). Cases that could not be appropriately evaluated for technical reasons (e.g., bad staining, low tumor area, etc) were designated as not evaluable. Spots with discordance in TIL category between pathologists were reviewed jointly and a single consensus category was established. In addition, the signals of different TIL subtypes were simultaneously measured using QIF with a multiplexed immunofluorescence protocol (Supplementary Fig. S4). Detailed description of the protocol and reagents is provided in the Supplementary Methods.

Determination of PD-L1 mRNA positivity

The cutoff for PD-L1 mRNA positivity was defined as the noise threshold of the system. This was determined by using the average QIF score of DapB (negative control bacterial gene) in situ hybridization in a serial section slide stained in the same batch as the experimental samples. PD-L1 mRNA scores between experiments were mean-normalized using the DapB scores from each independent run as reference. Cases with PD-L1 mRNA signal above the DapB were considered as positive and cases with scores equal to or lower were considered as negative. Cases with very low UbC (positive control) QIF scores (<60) were excluded from further analysis to rule out the possibility of false negative technical results.

Statistical analysis

Patient characteristics were compared using a t test for continuous variables and a χ2 test for categorical variables. Recurrence-free survival (RFS) and disease-specific survival (DSS) functions were compared using Kaplan–Meier estimates and statistical significance was determined using the log-rank test. A multivariate Cox proportional hazards model including age, tumor size, lymph node status, estrogen receptor, and HER2 status as covariates was built. All statistical analyses were performed using JMP Pro software (version 9.0.0, 2010, SAS Institute Inc.).

Results

PD-L1 mRNA assay validation

As shown in Supplementary Fig. S1A, PD-L1 mRNA signal was higher in PD-L1–transfected Mel624 cells than in parental cells and was recognized as multiple relatively small dots with predominant perinuclear cellular distribution (Supplementary Fig. S1A, red fluorescence channel). The PD-L1 mRNA QIF score was significantly higher than DapB (negative control) in FFPE preparations from PD-L1 Mel624 transfectants, but not in parental Mel624 cells (P < 0.001; Supplementary Fig. S1A). In samples from human placenta, PD-L1 mRNA signal was located predominantly in the trophoblastic cell compartment characterized by intense cytokeratin positivity (Supplementary Fig. S1B, left, green fluorescence channel). In contrast, the UbC mRNA signal was evenly distributed within the epithelial and mesenchymal areas of the chorionic villi (Supplementary Fig. S1B, central panels). As expected, the DapB mRNA signal was faint throughout the placental tissue, indicating a low background signal (Supplementary Fig. S1B, right).

In situ PD-L1 mRNA expression in breast cancer

In breast cancer samples, PD-L1 mRNA signal showed a similar dotted hybridization pattern and was predominantly located within the tumor (cytokeratin-positive) compartment (Fig. 1A, left). As expected, consecutive serial section samples hybridized with UbC and DapB mRNA probes showed high and low signal, respectively (Fig. 1A, middle and right). The cytokeratin signal and staining pattern were comparable between the serial section specimens.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

PD-L1 mRNA expression in breast cancer samples and distribution of scores in two cohorts. A, representative fluorescence microphotographs showing PD-L1, UbC, and DapB mRNA signal in consecutive sections from one PD-L1 mRNA-positive breast tumor on YTMA201 (histospot 263). PD-L1 positivity showed a microdotted staining pattern (inset) and the signal was allocated predominantly in the tumor compartment (red channel, top), as evident in the pancytokeratin-positive area (green channel, bottom). Nuclei were stained with DAPI. Bar, 100 μm. B and C, distribution of PD-L1 mRNA scores in cases from YTMA128 (B) and YTMA201 (C). The dashed black line indicates the DapB cutoff for positive/negative results. Values are expressed as arbitrary units of fluorescence.

In YTMA128, 178 spots (75%) were informative for all three mRNA targets and only 2 cases (0.8%) showed extremely low UbC mRNA scores and were excluded from the analysis. Ninety-eight cases (55.7%) showed positive PD-L1 mRNA signal (Fig. 1B). In YTMA201, 358 cases (89.5%) were informative and 22 cases (5.5%) were excluded for low UbC scores. In this cohort, 201 cases (59.5%) showed PD-L1 mRNA levels above the detection threshold (Fig. 1C). Although the serial section reproducibility of PD-L1 mRNA assay on YTMA245 was high (R2 = 0.73, Supplementary Fig. S2A), the regression between measurements in 2 cores from the same tumor block (intercore regression) on YTMA201 was considerably lower (R2 = 0.2, Supplemental Fig. S2B), suggesting that PD-L1 mRNA is a rather heterogeneous marker in breast cancer. Serial section regression of UbC was comparable with that of PD-L1 mRNA (R2 = 0.81, Supplementary Fig. S2C), but the intercore regression was higher using the same experimental conditions (R2 = 0.48, Supplementary Fig. S2D).

Consistent with previous findings in non–small cell lung cancer (35), breast tumor cells showed a predominant membranous-like PD-L1 protein staining pattern (Supplementary Fig. S3A) and the levels of PD-L1 mRNA showed a positive nonlinear relationship with PD-L1 protein in both breast cancer collections [regression coefficient (R) of 0.2 on YTMA128 (P = 0.01) and 0.16 on YTMA201 (P = 0.003), Supplementary Fig. S3C and S3D).

Characterization of lymphocytic infiltrates in breast cancer

Representative pictures of breast tumors cases showing different levels of TILs (scores 0–3+; see Materials and Methods) are depicted in Fig. 2A. Both YTMA128 and YTMA201 showed a high proportion of cases with low TILs (scores 0 and 1+) of 73.6% and 77.7%, respectively (Fig. 2B and C). The number of cases with more prominent lymphocytic infiltrates (scores 2 and 3+) was comparably low in both cohorts (16.5% on YTMA128 and 14.8% on YTMA201; Fig. 2B and C). Cases with elevated TILs showed significantly higher PD-L1 mRNA levels in both YTMA128 and YTMA201 (P < 0.01; Fig. 2D and E). The overall concordance for categorical TIL status determination between pathologists was 93% in YTMA128 (κ = 0.77) and 95% in YTMA201 (κ = 0.83).

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Presence of inflammatory infiltrates in breast carcinomas. A, representative microphotographs of hematoxylin/eosin preparations from breast cancer samples showing different TILs categories (TILs scores 0–3+). B and C, graphs showing the number and proportion of cases in each TILs category on YTMA128 (B) and YTMA201 (C). NE, not evaluable (see Materials and Methods). D and E, PD-L1 mRNA scores in cases with low TILs (score 0 and 1+) and high TILs (score 2 and 3+) from YTMA128 (D) and YTMA201 (E). The chart shows mean ± SEM of QIF scores, and the number within each bar indicates the amount of cases in each group.

Characterization of TIL subpopulations using multiplexed QIF revealed that cases from YTMA128 showing PD-L1 mRNA expression had 14.3% more CD3 signal, 21% more CD20 signal, and 8.8% higher CD8 signal than PD-L1 mRNA-negative tumors (Supplemental Fig. S4C). Similarly, PD-L1 mRNA expressing samples from YTMA201 showed 18.3% higher CD3 signal, 19.2% more CD20, and only 2.6% change in CD8 fluorescence (Supplementary Fig. S4D).

Clinicopathological associations of PD-L1 mRNA status and TILs breast carcinomas

In both YTMA128 and YTMA201, PD-L1 mRNA expression was significantly associated with the presence of elevated TILs (scores 2 and 3+, P = 0.04; Table 1), but not with age, tumor size, lymph node positivity, histologic grade, estrogen receptor positivity, and HER2 status. The presence of elevated TILs was significantly associated with ER-negative status in both YTMA128 and YTMA201 (P = 0.01 and 0.001, respectively; Table 2). The presence of prominent lymphocytic infiltrates was also significantly associated with younger age at diagnosis in YTMA128 (P = 0.006; Table 2). The latter association was also apparent in YTMA201, but did not reach statistical significance (P = 0.08; Table 2).

View this table:
  • View inline
  • View popup
Table 1.

PD-L1 mRNA associations on YTMA128 and YTMA201

View this table:
  • View inline
  • View popup
Table 2.

TILs associations on YTMA128 and YTMA201

Association of PD-L1 mRNA status and TILs with survival in breast cancer patients

In patients from YTMA201 with a relatively prolonged follow-up (median follow-up, 139 months; Supplementary Table S1), expression of PD-L1 mRNA in the tumor compartment was significantly associated with longer RFS (log-rank P = 0.01; Fig. 3A). The presence of elevated TILs in the TMA spot was also associated with longer RFS, although without reaching statistical significance (log-rank, P = 0.07; Fig. 3B). Concordant with PD-L1 mRNA, elevated levels of PD-L1 protein were also significantly associated with longer RFS in YTMA201 (Wimberly and colleagues, 2013, SABCS December 2013, manuscript in preparation).

Figure 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3.

PD-L1 mRNA positivity is associated with better outcome in breast carcinomas. A–D, Kaplan–Meier graphical analysis of the RFS and DSS in patients with breast cancer from YTMA201 according to PD-L1 mRNA status (A and C) or the amount of TILs (B and D). The number of subjects at risk in each group is indicated below the chart. The respective log-rank P values, HRs, and confidence intervals (CI) are indicated within each chart.

The presence of increased TILs was not significantly associated with the risk of recurrence in multivariate analysis (HR, 0.765; CI, 0.188–2.548; P = 0.67). In the multivariate model, PD-L1 mRNA expression in breast tumors from YTMA201 was significantly associated with lower risk of recurrence (HR, 0.268; CI, 0.099–0.721; P = 0.009; Table 3) and this association was independent from age, tumor size, lymph node status, histologic grade, ER status, HER2 status, and the presence of low or high TILs. As expected, larger tumor size (>2 cm) and tumor involvement of lymph nodes were significantly associated with higher recurrence risk (HR, 2.872; CI, 0.865–6.919; P = 0.02 and HR, 5.305; CI, 1.961–14.878; P = 0.001, respectively; Table 3). In addition, PD-L1 mRNA expression or the presence of elevated TILs showed a mild, nonstatistically significant association with longer DSS (log-rank P = 0.16 and 0.06, respectively; Fig. 3C and D).

View this table:
  • View inline
  • View popup
Table 3.

Multivariate analysis for RFS on YTMA201

Using the online biomarker validation tool SurvExpress (ref. 40; see Supplementary Fig. S5 and Supplementary Methods) containing information from 30 published breast cancer mRNA datasets, we identified 6 cohorts including PD-L1 mRNA records. Of them, only 1 had recurrence annotations and increased PD-L1 mRNA was significantly associated with longer RFS (Wang-Richardson GSE19615, P = 0.02; Supplementary Fig. S5A and S5B). The other five datasets had only overall survival data and high PD-L1 mRNA was marginally significantly associated with longer overall survival in one of them (Kao-Huang GSE20685, P = 0.05; Supplementary Fig. S5C and S5D). In the other 4 cohorts, elevated PD-L1 mRNA trended, but was not significantly associated with overall survival (TCGA, Ma-Sgroi GSE1378, Miller-Bergh GSE3494, and Enerly-Yakhini GSE19536; data not shown).

Discussion

Recent studies suggest that determination of PD-L1 status in tumor samples could help select patients for novel anti-PD-1/PD-L1 monoclonal antibody therapies (19). However, accurate determination of PD-L1 protein levels in FFPE tumor samples is limited by the absence of validated assays, reliable antibodies, and interpretative uncertainties (e.g., cutoff for positivity, marker heterogeneity). We describe herein a reproducible, antibody-independent assay for in situ PD-L1 mRNA measurement. A major strength of this method relies in the simultaneous measurement of a negative control indicator (DapB) that helps identifying the assay detection threshold and a positive control probe (UbC) used to exclude inadequate samples. Our data demonstrate that in situ PD-L1 mRNA expression can be measured in FFPE breast tumor samples and in TMAs. We also observed substantial variability between cores in PD-L1 expression, which will need to be taken into consideration when interpreting results from a single core biopsy of a large tumor. A limitation of our results is the lack of mRNA assessment by reverse transcription-PCR or array-based methods to establish concordance and quantification across mRNA measurement platforms. An advantage of the RNAscope technique is that it provides in situ measurement and can quantify mRNA in the epithelial cells within the TMA spot. As all other mRNA measurement methods grind the sample to produce the mRNA, from these methods the cellular source of the mRNA cannot be determined. However, we could validate the prognostic effect of PD-L1 mRNA expression in publicly available breast cancer mRNA datasets (Supplementary Fig. S5). Overall and despite the methodologic differences, the results are consistent with our findings measuring PD-L1 mRNA in situ.

A number of smaller studies have been published that assess expression levels of PD-L1 in breast cancer using IHC. A study by Ghebeh and colleagues (14), including 44 specimens with available frozen tissue and using the mouse monoclonal MIH1 clone for PD-L1 IHC, showed absence of signal in normal breast and expression of PD-L1 in 22 cases (50%). Fifteen of these cases showed signal in tumor cells with membranous/cytoplasmic pattern and were associated with higher histologic grade and hormone-receptor negativity. PD-L1–positive TILs were found in 18 of these cases (41%) and were associated with larger tumors, histologic grade III, HER2 positivity, and increased inflammatory infiltrates (14). In a subsequent study from the same group and using an expanded version of the cohort (N = 68), similar associations were found (22). Our results using mRNA measurements show that nearly 60% of breast carcinomas express PD-L1 transcripts and this was similar in two independent cohorts. However, no significant association with high grade/hormone receptor negativity was found. This difference might be due, at least in part, to the distinct properties and independent information provided by PD-L1 protein and mRNA molecules, as reported (33). Methodologic differences might also account for this apparent inconsistency. In fact, the MIH1 clone used in some studies failed validation using Western blot analysis and IHC in our laboratory together with two other commercially available antibodies (35). The same antibody clone was reported by others not to be suitable for FFPE samples (23).

Our results show that tumor PD-L1 mRNA expression is significantly associated with increased local immune cell infiltrates and with longer RFS. Moreover, the survival effect of PD-L1 mRNA was independent from other well-known prognostic factors such as tumor size, lymph node involvement, and hormone receptor/HER2 status, suggesting that PD-L1 mRNA is independently associated with favorable prognosis in breast cancer. However, these results are not in agreement with previous studies showing an adverse prognostic effect of PD-L1 expression by IHC in various malignancies, including melanoma, renal, urothelial, gastric, lung, and colorectal carcinomas (24–28). In contrast, our observations are consistent with 3 recent studies in metastatic melanomas, Merkel cell carcinomas and lung non–small cell carcinomas using the validated monoclonal antibody clone 5H1 and showing association of PD-L1 expression with TILs and longer survival (30, 31, 35). In addition, a recent study found positive association between PD-L1 IHC expression, presence of CD8-positive TILs, and overall survival using two different antibodies (monoclonal clone-27A2 from MBL and polyclonal ab82059 from Abcam) in a large TMA-based colorectal cancer cohort (32). The biologic determinants of the association between PD-L1 expression, increased TILs and better outcome are not well understood. For instance, tumor infiltration by CD8-positive T lymphocytes was recently shown to be associated with Tregs, PD-L1 protein and mRNA, and IDO expression in human metastatic melanomas. Moreover, induction of these immune inhibitory pathways in the tumor microenvironment required and was mediated by CD8-positive T cells and IFN-γ in a murine model (41). Therefore, it is possible that rather than an indication of total immune evasion, expression of PD-L1 by tumor cells might reflect the presence of antigenic-induced antitumor immune pressure mediated by TILs. Although partially ineffective, recruitment of TILs to the tumor microenvironment due to preserved chemotactic signals could still induce a partial antitumor effect and explain the observed survival benefit. Further studies will be required to clarify this in other solid tumor models and carefully weigh the effect of additional active costimulatory pathways.

Our data also show that the presence of elevated TILs was significantly associated with hormone receptor-negative tumors and with a clear trend towards longer survival (Fig. 3B–D). Similar findings have been reported by others (3–5) and point to the critical role of local immunity in limiting tumor progression, particularly in more aggressive triple-negative and basal-like breast neoplasms. In addition, increased TILs have also been shown to predict response to neoadjuvant chemotherapy in breast cancer (42, 43). However, our results show that the proportion of breast tumors with prominent lymphocytic infiltration is relatively low (∼15% of cases) and the prognostic information provided by TILs is limited.

Our analysis has a number of limitations. One major limitation is that it includes only retrospectively collected cases and that mature survival information was only available for one cohort. A second issue is that the use of TMAs may underestimate or overestimate the mRNA markers expression due to intratumoral heterogeneity of expression. Assays in the clinic always use whole slides and examination of high number of fields seen in a histologic section may attenuate the sampling effect of TMAs. Given these limitations, the results of this study should be considered as hypothesis generating. Although our results support the value of measuring PD-L1 in TMA samples, translation of these findings into the clinical setting could certainly benefit from using whole tissue section samples. This could better reflect the tissue distribution of PD-L1 and its topographical relationships with tumor cells and TILs. Determination of the amount of tumor tissue necessary to accurately measure PD-L1 in patient samples requires further evaluation, but should likely consider the tumor size, availability of sample material (core vs. tumor resection), clinical purpose (prognostic vs. predictive; adjuvant vs. neoadjuvant), and disease stage (one primary vs. multiple primaries vs. disseminated disease).

One key unaddressed issue is the potential of PD-L1 mRNA, alone or in combination with other markers such as PD-L1 protein, to predict response to anti-PD-1/PD-L1 therapies. Ongoing studies measuring PD-L1 mRNA and protein levels using QIF in whole tissue section specimens from patients treated with anti-PD-1 therapy might provide a better substrate to conclusively address the prognostic/predictive value of these markers.

Disclosure of Potential Conflicts of Interest

D.L. Rimm has a commercial research grant from Genoptix and is a consultant/advisory board member for Genoptix and Novartis. No potential conflicts of interest were disclosed by the other authors.

Authors' Contributions

Conception and design: K.A. Schalper, V. Velcheti, L. Pusztai, D.L. Rimm

Development of methodology: K.A. Schalper, D. Carvajal, H. Wimberly, J. Brown, D.L. Rimm

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): K.A. Schalper, V. Velcheti, D. Carvajal, H. Wimberly, J. Brown

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): K.A. Schalper, V. Velcheti, D. Carvajal, L. Pusztai, D.L. Rimm

Writing, review, and/or revision of the manuscript: K.A. Schalper, V. Velcheti, D. Carvajal, J. Brown, L. Pusztai, D.L. Rimm

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): K.A. Schalper, V. Velcheti, D.L. Rimm

Study supervision: K.A. Schalper, D.L. Rimm

Grant Support

This study was supported by the Breast Cancer Research Foundation (to D.L. Rimm and L. Pusztai) and a Novartis/Genoptix sponsored research agreement (to D.L. Rimm).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Acknowledgments

The authors acknowledge Lori Charette and the Yale Pathology Tissue Services for production of the high-quality TMAs used in this study.

Footnotes

  • Note: Supplementary data for this article are available at Clinical Cancer Research Online (http://clincancerres.aacrjournals.org/).

  • Received October 1, 2013.
  • Revision received February 10, 2014.
  • Accepted March 11, 2014.
  • ©2014 American Association for Cancer Research.

References

  1. 1.↵
    1. Jäger D,
    2. Jäger E,
    3. Knuth A
    . Immune responses to tumour antigens:implications for antigen specific immunotherapy of cancer. J Clin Pathol 2001;54:669–74.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Bianchini G,
    2. Qi Y,
    3. Alvarez R,
    4. Iwamoto T,
    5. Coutant C,
    6. Ibrahim NK,
    7. et al.
    Molecular anatomy of breast cancer and its prognostic value in estrogen receptor–positive and –negative cancers. J Clin Oncol 2010;28:4316–23.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Loi S,
    2. Sirtaine N,
    3. Piette F,
    4. Salgado R,
    5. Viale G,
    6. Van Eenoo F,
    7. et al.
    Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol 2013;31:860–7.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Mahmoud SM,
    2. Lee AH,
    3. Paish EC,
    4. Macmillan RD,
    5. Ellis IO,
    6. Green AR
    . The prognostic significance of B lymphocytes in invasive carcinoma of the breast. Breast Cancer Res Treat 2012;132:545–53.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Mahmoud SM,
    2. Paish EC,
    3. Powe DG,
    4. Macmillan RD,
    5. Grainge MJ,
    6. Lee AH,
    7. et al.
    Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol 2011;29:1949–55.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Janakiram M,
    2. Abadi YM,
    3. Sparano JA,
    4. Zang X
    . T cell coinhibition and immunotherapy in human breast cancer. Discov Med 2013;14:229–36.
    OpenUrl
  7. 7.↵
    1. Topalian SL,
    2. Drake CG,
    3. Pardoll DM
    . Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 2012;24:207–12.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Schreiber RD,
    2. Old LJ,
    3. Smyth MJ
    . Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011;331:1565–70.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Nurieva RI,
    2. Liu X,
    3. Dong C
    . Yin-Yang of costimulation: crucial controls of immune tolerance and function. Immunol Rev 2009;229:88–100.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Keir ME,
    2. Butte MJ,
    3. Freeman GJ,
    4. Sharpe AH
    . PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008;26:677–704.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Blank C,
    2. Mackensen A
    . Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. Cancer Immunol Immunother 2007;56:739–45.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Keir ME,
    2. Liang SC,
    3. Guleria I,
    4. Latchman YE,
    5. Qipo A,
    6. Albacker LA,
    7. et al.
    Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med 2006;203:883–95.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Zou W,
    2. Chen L
    . Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 2008;8:467–77.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Ghebeh H,
    2. Mohammed S,
    3. Al-Omair A,
    4. Qattan A,
    5. Lehe C,
    6. Al-Qudaihi G,
    7. et al.
    The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. Neoplasia 2006;8:190–8.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Hamanishi J,
    2. Mandai M,
    3. Iwasaki M,
    4. Okazaki T,
    5. Tanaka Y,
    6. Yamaguchi K,
    7. et al.
    Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A 2007;104:3360–5.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    1. Wu C,
    2. Zhu Y,
    3. Jiang J,
    4. Zhao J,
    5. Zhang XG,
    6. Xu N
    . Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. Acta Histochem 2006;108:19–24.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Nomi T,
    2. Sho M,
    3. Akahori T,
    4. Hamada K,
    5. Kubo A,
    6. Kanehiro H,
    7. et al.
    Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res 2007;13:2151–7.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Thompson RH,
    2. Kuntz SM,
    3. Leibovich BC,
    4. Dong H,
    5. Lohse CM,
    6. Webster WS,
    7. et al.
    Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res 2006;66:3381–5.
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    1. Topalian SL,
    2. Hodi FS,
    3. Brahmer JR,
    4. Gettinger SN,
    5. Smith DC,
    6. McDermott DF,
    7. et al.
    Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443–54.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Brahmer JR,
    2. Tykodi SS,
    3. Chow LQ,
    4. Hwu WJ,
    5. Topalian SL,
    6. Hwu P,
    7. et al.
    Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366:2455–65.
    OpenUrlCrossRefPubMed
  21. 21.↵
    1. Ghebeh H,
    2. Tulbah A,
    3. Mohammed S,
    4. Elkum N,
    5. Bin Amer SM,
    6. Al-Tweigeri T,
    7. et al.
    Expression of B7-H1 in BC patients is strongly associated with high proliferative Ki-67-expressing tumor cells. Int J Cancer 2007;121:751–8.
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Ghebeh H,
    2. Barhoush E,
    3. Tulbah A,
    4. Elkum N,
    5. Al-Tweigeri T,
    6. Dermime S
    . FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk BC patients: implication for immunotherapy. BMC Cancer 2008;8:57.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Gadiot J,
    2. Hooijkaas AI,
    3. Kaiser AD,
    4. van Tinteren H,
    5. van Boven H,
    6. Blank C
    . Overall survival and PD-L1 expression in metastasized malignant melanoma. Cancer 2010;117:2192–201.
    OpenUrlPubMed
  24. 24.↵
    1. Zang X,
    2. Allison JP
    . The B7 family and cancer therapy: costimulation and coinhibition. Clin Cancer Res 2007;13:5271–9.
    OpenUrlAbstract/FREE Full Text
  25. 25.↵
    1. Hino R,
    2. Kabashima K,
    3. Kato Y,
    4. Yagi H,
    5. Nakamura M,
    6. Honjo T,
    7. et al.
    Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer 2010;116:1757–66.
    OpenUrlCrossRefPubMed
  26. 26.↵
    1. Hasan A,
    2. Ghebeh H,
    3. Lehe C,
    4. Ahmad R,
    5. Dermime S
    . Therapeutic targeting of B7-H1 in breast cancer. Expert Opin Ther Targets 2011;15:1211–25.
    OpenUrlCrossRefPubMed
  27. 27.↵
    1. Mu CY,
    2. Huang JA,
    3. Chen Y,
    4. Chen C,
    5. Zhang XG
    . High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med Oncol 2011;28:682–8.
    OpenUrlCrossRefPubMed
  28. 28.↵
    1. Song M,
    2. Chen D,
    3. Lu B,
    4. Wang C,
    5. Zhang J,
    6. Huang L,
    7. et al.
    PTEN loss increases PD-L1 protein expression and affects the correlation between PD-L1 expression and clinical parameters in colorectal cancer. PLoS ONE 2013;8:e65821.
    OpenUrlCrossRefPubMed
  29. 29.↵
    1. Konishi J,
    2. Yamazaki K,
    3. Azuma M,
    4. Kinoshita I,
    5. Dosaka-Akita H,
    6. Nishimura M
    . B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res 2004;10:5094–100.
    OpenUrlAbstract/FREE Full Text
  30. 30.↵
    1. Taube JM,
    2. Anders RA,
    3. Young GD,
    4. Xu H,
    5. Sharma R,
    6. McMiller TL,
    7. et al.
    Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012;4:127ra137.
    OpenUrl
  31. 31.↵
    1. Lipson EJ,
    2. Vincent JG,
    3. Loyo M,
    4. Kagohara LT,
    5. Luber BS,
    6. Wang H,
    7. et al.
    PD-L1 expression in the merkel cell carcinoma microenvironment: association with inflammation, merkel cell polyomavirus, and overall survival. Cancer Immunol Res 2013;1:54–63.
    OpenUrlAbstract/FREE Full Text
  32. 32.↵
    1. Droeser RA,
    2. Hirt C,
    3. Viehl CT,
    4. Frey DM,
    5. Nebiker C,
    6. Huber X,
    7. et al.
    Clinical impact of programmed cell death ligand 1 expression in colorectal cancer. Eur J Cancer 2013;49:2233–42.
    OpenUrlCrossRefPubMed
  33. 33.↵
    1. Bordeaux JM,
    2. Cheng H,
    3. Welsh AW,
    4. Haffty BG,
    5. Lannin DR,
    6. Wu X,
    7. et al.
    Quantitative in situ measurement of estrogen receptor mRNA predicts response to tamoxifen. PLoS ONE 2012;7:e36559.
    OpenUrlCrossRefPubMed
  34. 34.↵
    1. Rajbhandari P,
    2. Schalper KA,
    3. Solodin NM,
    4. Ellison-Zelski SJ,
    5. Ping Lu K,
    6. Rimm DL,
    7. et al.
    Pin1 modulates ERalpha levels in breast cancer through inhibition of phosphorylation-dependent ubiquitination and degradation. Oncogene 2013;33:1438–47.
    OpenUrlPubMed
  35. 35.↵
    1. Velcheti V,
    2. Schalper KA,
    3. Carvajal DE,
    4. Anagnostou VK,
    5. Syrigos KN,
    6. Sznol M,
    7. et al.
    Programmed death ligand-1 expression in non-small cell lung cancer. Lab Invest 2014;94:107–16.
    OpenUrlCrossRefPubMed
  36. 36.↵
    1. Dolled-Filhart MP,
    2. Rimm DL
    . Tissue microarray technology: a new standard for molecular evaluation of tissue? Princ Pract Oncol Technol Update 2002;16:1–11.
    OpenUrl
  37. 37.↵
    1. McCabe A,
    2. Dolled-Filhart M,
    3. Camp RL,
    4. Rimm DL
    . Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis. J Natl Cancer Inst 2005;97:1808–15.
    OpenUrlAbstract/FREE Full Text
  38. 38.↵
    1. Camp RL,
    2. Chung GG,
    3. Rimm DL
    . Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med 2002;8:1323–7.
    OpenUrlCrossRefPubMed
  39. 39.↵
    1. Klintrup K,
    2. Mäkinen JM,
    3. Kauppila S,
    4. Väre PO,
    5. Melkko J,
    6. Tuominen H,
    7. et al.
    Inflammation and prognosis in colorectal cancer. Eur J Cancer 2005;41:2645–54.
    OpenUrlCrossRefPubMed
  40. 40.↵
    1. Aguirre-Gamboa R,
    2. Gomez-Rueda H,
    3. Martínez-Ledesma E,
    4. Martínez-Torteya A,
    5. Chacolla-Huaringa R,
    6. Rodriguez-Barrientos A,
    7. et al.
    SurvExpress: an online biomarker validation tool and database for cancer gene expression data using survival analysis. PLoS ONE 2013;8:e74250.
    OpenUrlCrossRefPubMed
  41. 41.↵
    1. Spranger S,
    2. Spaapen RM,
    3. Zha Y,
    4. Williams J,
    5. Meng Y,
    6. Ha TT,
    7. et al.
    Up-regulation of PD-L1, IDO, and tregs in the melanoma tumor microenvironment is driven by CD8+ T cells. Sci Transl Med 2013;5:200ra116.
    OpenUrlAbstract/FREE Full Text
  42. 42.↵
    1. Ono M,
    2. Tsuda H,
    3. Shimizu C,
    4. Yamamoto S,
    5. Shibata T,
    6. Yamamoto H,
    7. et al.
    Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer. Breast Cancer Res Treat 2012;132:793–805.
    OpenUrlCrossRefPubMed
  43. 43.↵
    1. West NR,
    2. Milne K,
    3. Truong PT,
    4. Macpherson N,
    5. Nelson BH,
    6. Watson PH
    . Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer. Breast Cancer Res 2011;13:R126.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top
Clinical Cancer Research: 20 (10)
May 2014
Volume 20, Issue 10
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Clinical Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
In Situ Tumor PD-L1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast Carcinomas
(Your Name) has forwarded a page to you from Clinical Cancer Research
(Your Name) thought you would be interested in this article in Clinical Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
In Situ Tumor PD-L1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast Carcinomas
Kurt A. Schalper, Vamsidhar Velcheti, Daniel Carvajal, Hallie Wimberly, Jason Brown, Lajos Pusztai and David L. Rimm
Clin Cancer Res May 15 2014 (20) (10) 2773-2782; DOI: 10.1158/1078-0432.CCR-13-2702

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
In Situ Tumor PD-L1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast Carcinomas
Kurt A. Schalper, Vamsidhar Velcheti, Daniel Carvajal, Hallie Wimberly, Jason Brown, Lajos Pusztai and David L. Rimm
Clin Cancer Res May 15 2014 (20) (10) 2773-2782; DOI: 10.1158/1078-0432.CCR-13-2702
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosure of Potential Conflicts of Interest
    • Authors' Contributions
    • Grant Support
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Variability in Assessing Response in Metastatic Colorectal Cancer
  • 18FDG PET-MRI of Breast Tumors: Feasibility
  • TP53 in Breast Cancer
Show more Imaging, Diagnosis, Prognosis
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • CCR Focus Archive
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Clinical Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Clinical Cancer Research
eISSN: 1557-3265
ISSN: 1078-0432

Advertisement